IDH1 and central nervous system cancer: The median PFS was 31 months for patients with IDH mutant gliomas harboring +7q, +8q, −9p, and/or −11p compared with 78 months for all other IDH mutant gliomas (hazard ratio = 0.254; 95% CI: 0.128–0.506; p < 0.0001).